It has been studied for use by rectal administration in the treatment of prostate cancer in men as well. The medication was introduced in the U.S. in 1947 by Schering as Synestrol and in France in 1948 as Cycladiene.
The drug's use for rectal administration in treating prostate cancer in men has been studied, and it was first introduced to the U.S. market in 1947 under the name Synestrol by Schering, and later in France as Cycladiene in 1948.